Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Elf's Sanofi and L'Oreal's Synthelabo announce merger to create a major French pharmaceutical company.
In 1999, Sanofi acquired Synthelabo, another French pharmaceutical company, for $8.5 billion, forming Sanofi-Synthelabo.
A look back at Sanofi's merger with Synthelabo, which was completed on May 18, 1999.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Sanofi (owned by Elf Aquitaine) and Synthelabo (owned by L'Oreal) merged in late 1998/1999 to create Sanofi-Synthelabo, a major French pharmaceutical company. The deal was driven by parent companies seeking to create a globally competitive pharma platform. Sanofi-Synthelabo later acquired Aventis in 2004 to become Sanofi-Aventis.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Synthelabo S.A. (this deal) | 1998 | $11.0B | 84 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
| Sanofi SA / Protein Sciences Corp. | 2017 | $650M | 72 |
← Browse all deals · How we score deals
More: 1998 deals · Sanofi SA deals · Cardiovascular deals